Skip to main content
16 search results for:

Dacarbazine 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 16-08-2017 | Melanoma | News | Article

    Final BRIM-3 data confirm vemurafenib survival benefit over dacarbazine

    Final data from the BRIM-3 trial show that overall survival remains significantly better with vemurafenib than with dacarbazine when given to treatment-naïve patients with BRAF V600 mutation–positive metastatic melanoma.

  2. 06-03-2017 | Melanoma | Article

    Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

    Dummer R et al.  Lancet Oncol  2017; 18(4): 435-445. doi:10.1016/S1470-2045(17)30180-8

  3. 12-12-2017 | Hodgkin lymphoma | News | Article

    Brentuximab vedotin may improve outcome in advanced Hodgkin lymphoma

    A treatment regimen incorporating the anti-CD30 antibody–drug conjugate brentuximab vedotin is more effective than standard therapy with doxorubicin, bleomycin, vinblastine, and dacarbazine when used as a frontline therapy in patients with advanced Hodgkin lymphoma, phase III trial data show.

  4. 28-09-2018 | Hematologic cancers | News | Article

    In other news: Hematologic cancer focus

    . --- Sequential brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (AVD) leads to “robust outcomes” in patients aged 60 years or older with a new diagnosis of HL, a “historically difficult-to-treat patient population,” report Andrew Evens (Rutgers Cancer Institute of New Jersey, New Brunswick, USA) and team in the Journal of Clinical Oncology .

  5. 20-09-2018 | Hodgkin lymphoma | News | Article

    Hormonal biomarker shows ovarian toxicity of Hodgkin lymphoma treatment

    The study, by Richard Anderson (University of Edinburgh, UK) and colleagues, found that antimüllerian hormone concentration, an indirect marker of ovarian reserve, decreased substantially during treatment with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), AVD, or bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisolone (BEACOPP-14 or escalated BEACOPP).

  6. play
    05-04-2018 | Uveal melanoma | Podcast | Video

    SUMIT: Selumetinib in metastatic uveal melanoma

    Advisory Board member and study author Paul Nathan, from the Mount Vernon Cancer Centre in Middlesex, UK, discusses the phase III SUMIT trial, which evaluated the addition of the MEK inhibitor selumetinib to dacarbazine in patients with metastatic uveal melanoma.

  7. 14-03-2017 | Melanoma | News | Article

    Binimetinib extends NRAS-mutated metastatic melanoma PFS

    Binimetinib could be incorporated into the treatment pathway of patients with advanced melanoma harboring NRAS mutations, say researchers who found a progression-free survival benefit with the MEK inhibitor over dacarbazine.

  8. 22-03-2018 | FDA | News | Article
    approvalsWatch

    First-line brentuximab vedotin approved for advanced Hodgkin lymphoma

    The decision follows positive findings from the ECHELON-1 trial comparing outcomes for patients given a regimen of doxorubicin, vinblastine and dacarbazine alongside bleomycin or brentuximab vedotin.

  9. 31-10-2017 | Hodgkin lymphoma | News | Article

    PET-guided treatment de-escalation feasible in Hodgkin lymphoma

    “If so, the reluctance to use eBEACOPP owing to its toxicity profile might then be offset by the much increased efficacy and reduced treatment time as compared with doxorubicin, bleomycin, vinblastine, and dacarbazine.”

  10. 11-11-2016 | Treatment | Article

    Combinatorial immunotherapy for melanoma

    The second phase III trial of 502 patients with treatment naive advanced melanoma compared dacarbazine plus ipilimumab dosed at 10 mg/kg –1 versus dacarbazine alone.

  11. 21-04-2017 | Lymphoma | Feature | Article

    Lymphoma in practice: Professor Anas Younes speaks to medwireNews

    The open-label, ECHELON-1 trial of patients with advanced classical Hodgkin lymphoma compares first-line brentuximab vedotin given alongside doxorubicin, vinblastine, and dacarbazine with a conventional ABVD regimen (doxorubicin, bleomycin, vinblastine, and dacarbazine).

  12. 26-06-2017 | Soft-tissue sarcoma | Conference coverage | Article
    ASCO 2017

    Aldoxorubicin has activity in advanced soft tissue sarcoma

    Among 433 patients who had relapsed or were refractory to prior chemotherapy, median PFS was comparable between the participants who were randomly assigned to receive aldoxorubicin 350 mg/m 2 every 3 weeks and those treated with investigators’ choice of pazopanib, gemcitabine/docetaxel, dacarbazine, doxorubicin, or ifosfamide, at 4.11 and 2.96 months, respectively, and a nonsignificant hazard ratio (HR) of 0.81.

  13. 02-03-2017 | Liquid biopsy | Review | Article

    Integrating liquid biopsies into the management of cancer

    Of note, MGMT silencing by promoter methylation has been used to identify patients with GBM or metastatic colorectal cancer who are most likely to respond to the alkylating agents dacarbazine or temozolomide 145 .

  14. 29-12-2016 | Lymphoma | Article

    The landscape of new drugs in lymphoma

    Several studies are currently testing the effectiveness of anti-PD-1 antibodies in combination with brentuximab vedotin, or in combination with chemotherapy, including a regimen containing doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) for patients with HL and R-CHOP for those with NHL (Table 2).

  15. 24-07-2015 | Treatment | Article

    Evolving synergistic combinations of targeted immunotherapies to combat cancer

    Whereas the first combination did not add toxicity or benefit over ipilimumab alone, the dacarbazine and ipilimumab combination conferred a survival benefit over dacarbazine alone.

  16. 30-09-2017 | Metastatic melanoma | Article

    Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

    Chapman PB et al.  Ann Oncol  2017; 28(10): 2581-2587. doi:10.1093/annonc/mdx339

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.